For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The United Kingdom, Germany, France, Italy, Spain & Rest of Europe are the countries considered for this market analysis. The hemostats and tissue sealants market was valued at $ xx million in 2018 and is expected to reach $ xx million by 2027. This particular regional market is growing at CAGR of 7.46% from 2019 to 2027.
The United Kingdom has the second largest market for hemostasis and sealing agents in Europe, but is the fastest growing market because of a few promotional incentives by governmental institutions. For example, the National Health Service (NHS) is offering low-cost to free-of-cost treatments to unemployed or retired patients who undergo treatments in NHS run hospitals. Also, a well-integrated healthcare network in the country helps drive market growth significantly.
Smith & Nephew PLC, Integra Lifesciences Corp., Advanced Medical Solutions (AMS) Group PLC, Baxter International Inc., B.Braun Melsungen AG, Cohera Medical Inc., Cryolife Inc., CSL Behring, Hyperbranch Medical Technology, Inc. (Acquired by Stryker), Johnson & Johnson, Medtronic PLC, Pfizer, Inc. and C.R. Bard, Inc. are the chief competing market players in the Europe hemostats and tissue sealants market.